Intracranial Hypertension Associated With Testosterone Therapy In Female-To-Male Transgender Patients: A Case Report And Literature Review

Semin Ophthalmol. 2023 Aug;38(6):559-564. doi: 10.1080/08820538.2023.2169578. Epub 2023 Jan 19.

Abstract

We highlight a case of intracranial hypertension secondary to exogenous testosterone in a female-to-male transgender patient and present a systematic review of similar cases. Our review identified 19 female-to-male transgender individuals with intracranial hypertension. The mean age was 24.2 years and most common presenting symptom was headache (78.9% of patients). The most frequently associated ocular symptoms were transient visual obscurations (42.1%) and blurred vision (21.1%). Onset of symptoms occurred concurrently with exogenous testosterone therapy in 89.5% of the patients. The most common treatments were acetazolamide (89.5%), topiramate (31.6%), and alteration in hormone regimen (21.1%); four cases required surgery. These findings aid clinicians treating intracranial hypertension in patients undergoing gender affirmation therapy in a conscientious, patient-centered manner.

Keywords: Female-to-male; Intracranial hypertension; Ophthalmology; Testosterone; Transgender.

Publication types

  • Systematic Review
  • Case Reports

MeSH terms

  • Acetazolamide / adverse effects
  • Adult
  • Female
  • Humans
  • Intracranial Hypertension* / chemically induced
  • Intracranial Hypertension* / diagnosis
  • Male
  • Testosterone / adverse effects
  • Transgender Persons*
  • Vision Disorders / etiology
  • Young Adult

Substances

  • Testosterone
  • Acetazolamide